Acute gastrointestinal graft-versus-host disease is associated with reductions of secondary bile acids following allogeneic hematopoietic cell transplantation
Frontiers in Microbiology · 09.07.2026 · 17
DOI: 10.3389/fmicb.2026.1818647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 09.07.2026. Verfasst von Robin Cagle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS.
Abstract (Originalsprache)
Introduction
Allogeneic hematopoietic cell transplantation (HCT) can cure hematologic malignancies, but 30-70% of recipients experience acute graft-versus-host disease (GvHD). GvHD is associated with perturbations in the gut microbiome. Bile acids are host derived compounds that are transformed by gut bacteria and bind to specific host cell receptors, informing our hypothesis that changes in bile acid-metabolizing gut bacteria alter bile acid levels to affect gut physiology and immunity during GvHD.
Methods
In a longitudinal case-control study of patients with and without acute gut GvHD, we characterized bile acid concentrations and the gut microbiome in stool.
Results
Primary and conjugated bile acid levels were similar regardless of gut GvHD status, but endogenous secondary bile acid concentrations were associated with gut GvHD ( p = 0.009). We observed 4.4-fold lower levels of endogenous secondary bile acids in GvHD, particularly lithocholic acid and derivatives ( p = 0.004/p adjusted = 0.02, fold change (FC) = 0.23). There was a 100-fold lower median abundance ( p = 0.002 and FC < 0.01) and 20-fold lower median diversity of bacterial bile acid 7α-dehydroxylation ( bai ) genes ( p = 0.0007 and FC < 0.05) in patients with GvHD.
Discussion
This provides evidence that acute gut GvHD patients are deficient in microbial bai genes that make secondary bile acids.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
- Department of Microbiology, University of Washington, Seattle, WA, United States.
- Northwest Metabolomics Research Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, United States.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
- Division of Hematology and Oncology, University of Washington, Seattle, WA, United States.
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Förderung
- NHGRI NIH HHS
Zitieren
APA
Cagle, R., Proll, S., Minot, S. S., Purcell, H., Zhu, W., Djukovic, D., Liu, C., Fiedler, T., DeMeules, M., Mielcarek, M., Srinivasan, S., Raftery, D., Wu, M., Pergam, S. A., & Fredricks, D. N. (2026). Acute gastrointestinal graft-versus-host disease is associated with reductions of secondary bile acids following allogeneic hematopoietic cell transplantation. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1818647
Vancouver
Cagle R, Proll S, Minot SS, Purcell H, Zhu W, Djukovic D, et al. Acute gastrointestinal graft-versus-host disease is associated with reductions of secondary bile acids following allogeneic hematopoietic cell transplantation. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1818647
BibTeX
@article{Cagle2026,
author = {Cagle, Robin and Proll, Sean and Minot, Samuel S and Purcell, Hayley and Zhu, Wentao and Djukovic, Danijel and Liu, Congzhou and Fiedler, Tina and DeMeules, Martha and Mielcarek, Marco and Srinivasan, Sujatha and Raftery, Daniel and Wu, Michael and Pergam, Steven A and Fredricks, David N},
title = {Acute gastrointestinal graft-versus-host disease is associated with reductions of secondary bile acids following allogeneic hematopoietic cell transplantation},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1818647}
}
EUVIMED